Vc Thoughts, Health, Dna, Rna, Healthcare.
of DNA-based therapies using AAVs as a delivery vehicle. Until June 2021, 26% of clinical trials using AAV-based therapies were done in ophthalmology indications, followed by metabolic (20%), neurological (17%), and haematological (14%). With the majority in preclinical development, six assets were